Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725209 | 0.85 | TAS2R14 (0.42) | PIK3C2BP2RX7TAS2R14IDO1CYP2D6 | |
| SCHEMBL15532671 | 0.85 | P2RX7 (0.41) | PDCD1CD274PIK3C2BP2RX7TAS2R14 | |
| SCHEMBL18753207 | 0.82 | IDO1 (0.41) | PIK3C2BP2RX7TAS2R14IDO1CYP2D6 | |
| SCHEMBL31751977 | 0.82 | GABRA1 (0.46) | P2RX7TAS2R14IDO1CYP2D6SLC6A2 | |
| SCHEMBL10176579 | 0.82 | PDCD1 (0.50) | PDCD1CD274ALDH1A1GAAATM | |
| SCHEMBL11967099 | 0.82 | GABRA1 (0.46) | P2RX7TAS2R14IDO1CYP2D6SLC6A2 | |
| SCHEMBL44837 | 0.81 | IDO1 (0.57) | IDO1POLQKDM4EALDH1A1ATM | |
| SCHEMBL29389277 | 0.81 | IDO1 (0.57) | IDO1POLQKDM4EALDH1A1ATM | |
| SCHEMBL724189 | 0.80 | P2RX7 (0.41) | PIK3C2BP2RX7TAS2R14IDO1CYP2D6 | |
| SCHEMBL4550354 | 0.80 | MAOB (0.45) | P2RX7TAS2R14IDO1CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021000933-A1 | PYRIMIDINONE COMPOUNDS AS CHYMASE INHIBITORS AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-01-07 | — | — | WO | disclosed |
| EP-2432321-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8138340-B2 | Bicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-20 | — | — | US | disclosed |
| EP-2358688-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010135504-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010077883-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-1786814-B1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20090306123-A1 | Bicyclononene derivaties | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1786814-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021402-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306123-A1 | Bicyclononene derivaties | REN, ACE, CYP51A1 | PDCD1 2711/4885CD274 3912/4885PIK3C2B 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.